Legal & General Group Plc Purchases New Shares in Celcuity, Inc. $CELC

Legal & General Group Plc acquired a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 16,850 shares of the company’s stock, valued at approximately $1,763,000.

Other large investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its position in shares of Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after buying an additional 86 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Celcuity by 15.1% in the second quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock worth $99,000 after acquiring an additional 124 shares in the last quarter. US Bancorp DE grew its position in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. Intech Investment Management LLC increased its stake in Celcuity by 1.4% during the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after acquiring an additional 183 shares during the last quarter. Finally, Aristides Capital LLC increased its stake in Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after acquiring an additional 303 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CELC has been the subject of several analyst reports. Leerink Partners set a $155.00 price objective on Celcuity in a research note on Tuesday, June 2nd. Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Stifel Nicolaus decreased their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Guggenheim raised their price target on Celcuity from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Tuesday, September 1st. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $154.55.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $95.70 on Monday. The firm has a market capitalization of $4.68 billion, a PE ratio of -22.26 and a beta of 0.19. The business has a 50 day simple moving average of $94.58 and a two-hundred day simple moving average of $106.78. Celcuity, Inc. has a 1 year low of $44.42 and a 1 year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, equities analysts predict that Celcuity, Inc. will post -4.75 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.